Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the historical development of finasteride's approval for benign prostatic hyperplasia and discusses a trial that found decreased low-grade prostate cancer incidence but increased high-grade prostate cancer, with differing expert opinions on its use for cancer prevention.

Merck will refund the cost of the drug finasteride if it doesn't improve symptoms within six months or if the patient needs surgery within two years.

This study reports an increase in the use of tamsulosin/finasteride for benign prostatic syndrome in Germany but highlights that reliable comparisons with monotherapies are lacking due to study design deficiencies.

In this study, Saw Palmetto at a physiological dose partially inhibited 5-α-reductase and improved hormonal balance, inflammation, and mitochondrial function, with synergy observed when combined with Lycopene, L-Arginine, and Astaxanthin, enhancing male prostatic and endocrine health without endocrine side effects.

This review paper provides a comprehensive overview of Dutasteride, detailing its pharmacological properties, mechanisms, and therapeutic applications, particularly for androgenetic alopecia and benign prostatic hyperplasia, and discusses its potential use in prostate cancer prevention and transgender medicine.

This study found that Sonirid Duo, a combination of tamsulosin and finasteride, significantly improved symptoms and quality of life in patients with BPH over 12 months.

This review discusses finasteride, developed by Merck, as a treatment for benign prostatic hyperplasia and notes its potential effectiveness for male androgenetic alopecia, but reports no new clinical results.

This review discusses the pharmacologic effects, safety, and efficacy of dutasteride and finasteride for BPH, finding similar clinical benefits but greater DHT reduction with dutasteride and reports no new trial results.

This article discusses the long-standing use and safety of opioids in anaesthesia, noting that respiratory depression is a manageable side effect due to the availability of opioid antagonists.

This study aimed to estimate the value of urine prostate specific antigen (uPSA) as a marker for benign prostatic hyperplasia (BPH) but reported no new clinical findings.

This study found that ureteroileal anastomosis with direct intraluminal visualization had a 4.2% stricture rate, which compares favorably to other techniques with rates between 3.5% and 11.1%.

In this study, significantly fewer men treated with finasteride for moderate to severe BPH symptoms experienced acute urinary retention or required subsequent BPH-related surgery compared to placebo-treated patients.

In this study, short-term treatment with lovastatin showed no effect on symptom severity, prostate volume, or PSA levels in men with prostatic enlargement from presumed benign prostatic hyperplasia.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

This review examines microbial production and applications of gluconic acid, focusing on the enzymatic processes involved, and offers no new experimental results.

This study found that finasteride significantly alters urinary steroid profiles, complicating the detection of steroid abuse in doping-control analysis by potentially causing false-negative results.

This study found that diagnosing non-classical 3 beta-hydroxysteroid dehydrogenase deficiency solely based on elevated serum or urinary 5-ene-steroids may not be reliable.

In this study, researchers found that taking Saw palmetto and Pygeum africana supplements for five days altered the urinary steroid profile in a way that may interfere with the steroidal module of the Athlete Biological Passport.

In this study, correlations between urinary and serum androgen metabolites were examined in girls aged 6-13, revealing that summed urinary metabolites strongly correspond with circulating androstenedione and testosterone levels, though individual variations depend on participant characteristics such as age and body measurements.

This study found no correlation between androgenic alopecia and lower urinary tract symptoms or prostate volume in men who underwent a Green Light Laser Vaporization Procedure of the prostate.

This randomized, placebo-controlled trial reported that USPlus PRO saw palmetto extract significantly improved lower urinary tract symptoms, including voiding, incomplete emptying, and weak stream, as well as sexual function in males over 12 weeks, while maintaining a favorable safety profile.

This study found that after 12 weeks of taking the trial product SHPro®, participants reported improvements in prostate symptom scores and erectile function, with confirmed safety.

This review discusses recent advancements and new approvals in the medical treatment of lower urinary tract symptoms, particularly highlighting drugs for nocturia and ongoing trials for multiple related conditions, while reporting no new clinical results.

This article reviews the management of lower urinary tract symptoms, highlighting drug therapy advancements that have reduced the frequency of surgical interventions.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.

This study suggests that combining LMWHA solution and HCO might improve mild to moderate urinary incontinence in women with GSM, potentially offering benefits over HA therapy alone, but further research is needed.

This review discusses medical treatments for lower urinary tract symptoms suggestive of benign prostatic hyperplasia, focusing on their effects, side-effects, and implications for treatment goals, but reports no new clinical results.

This study found that the risk of urinary stone disease increased significantly in patients with severe androgenetic alopecia, and that testosterone deficiency was more frequent among these patients.

This study found that individuals with a nondipper blood pressure pattern had significantly higher 24-hour urinary aldosterone levels than those with a dipper pattern.